US5223482A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
Assignee: Scios LLC
•
Filing: 1989-06-06
•
Granted: 1993-06-29
•
Expires: 2009-06-06
Abstract
Abstract DNA sequences encoding β-amyloid-related proteins associated with Alzheimer's disease are disclosed. Also provided herein is a DNA sequence encoding a novel protease inhibitor. These sequences are used in producing or constructing recombinant β-amyloid core protein, β-amyloid-related proteins and recombinant or synthetic immunogenic peptides. Antibodies generated against the recombinant proteins or immunogenic peptides derived therefrom can be used for cerebral fluid or serum protein diagnosis of Alzheimer's disease.
Inventors
- 👤 James W. Schilling, Jr.
- 👤 Phyllis A. Ponte
- 👤 Barbara Cordell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 18:22
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61P; A61P1/00; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4711; C07K14/81; C07K14/8107; C07K14/811; C07K14/8114; C07K16/00; C07K16/18; C07K16/38; C12N15/70; C12N15/71; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6883; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6893; G01N33/6896; A61K; A61K2123/00; A61K38/00; C12N2710/00; C12N2710/00011; C12N2710/24011; C12N2710/24111; C12N2710/24141; C12N2710/24143; C12Q2600/00; C12Q2600/158; G01N2800/00; G01N2800/28; G01N2800/2814; G01N2800/2821; Y; Y02; Y02A; Y02A50/00; Y02A50/30; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S435/91; Y10S530/00; Y10S530/827; Y10S530/839
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
13 words
An essentially pure protease inhibitor consisting essentially of the amino acid sequence: ##STR6##
Claim 2
Dependent Claim
13 words
An essentially pure protease inhibitor consisting essentially of the amino acid sequence: ##STR6##
Claim 3
Dependent Claim
17 words
A pharmaceutical composition comprising the protease inhibitor of claim 1 in admixture with a pharmaceutically acceptable excipient.
Claim 4
Dependent Claim
26 words
A method for treating acute pancreatitis in a subject with method comprises administering to said subject an effective amount of the protease inhibitor of claim 1.
Claim 5
Dependent Claim
37 words
An analog of human amyloid plaque core protein protease inhibitor wherein the amino acid corresponding to arginine at position 13 in the sequence ##STR7## is substituted with an aromatic amino acid, said analog exhibiting chymotrypsin inhibitory activity.
Claim 6
Dependent Claim
37 words
An analog of human amyloid plaque core protein protease inhibitor wherein the amino acid corresponding to arginine at position 13 in the sequence ##STR7## is substituted with an aromatic amino acid, said analog exhibiting chymotrypsin inhibitory activity.
Claim 7
Dependent Claim
21 words
The analog of claim 4 wherein said aromatic amino acid is selected from the group consisting of phenylalanine, tyrosine and tryptophan.
Claim 8
Dependent Claim
18 words
A pharmaceutical composition comprising a pharmaceutically acceptable excipient carrier and the protease analog as claimed in claim 4.
Claim 9
Dependent Claim
38 words
An analog of human amyloid plaque core protein protease inhibitor wherein the amino acid corresponding to arginine at position 13 in the sequence: ##STR8## is substituted with neutral hydrophobic amino acid, said analog exhibiting human elastase inhibitory activity.
Claim 10
Dependent Claim
38 words
An analog of human amyloid plaque core protein protease inhibitor wherein the amino acid corresponding to arginine at position 13 in the sequence: ##STR8## is substituted with neutral hydrophobic amino acid, said analog exhibiting human elastase inhibitory activity.
Claim 11
Dependent Claim
22 words
The analog of claim 7 wherein said neutral hydrophobic amino acid is selected from the group consisting of leucine, methionine and valine.
Claim 12
Dependent Claim
18 words
A pharmaceutical composition comprising a pharmaceutically acceptable excipient carrier and the protease analog as claimed in claim 7.
Claim 13
Dependent Claim
18 words
A pharmaceutical composition comprising a pharmaceutically acceptable excipient carrier and the protease analog as claimed in claim 8.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-06-28 | 1996-12-28 | 1997-06-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-06-28 | 2000-12-28 | 2001-06-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-06-28 | 2004-12-28 | 2005-06-29 | $7700.00 | Window Closed / Lapsed |